Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms VISMOLY
- 31 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 31 Mar 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 31 Mar 2015 Planned End Date changed from 1 Aug 2016 to 1 Apr 2015 as reported by ClinicalTrials.gov record.